| Symbol | PRME |
|---|---|
| Name | PRIME MEDICINE, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Address | 60 FIRST STREET, CAMBRIDGE, Massachusetts, 02141, United States |
| Telephone | +1 617 - 465-0013 |
| Fax | — |
| — | |
| Website | https://www.primemedicine.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001894562 |
| Description | Prime Medicine Inc is a biotechnology company committed to delivering genetic therapies to address diseases by deploying gene editing technology, Prime Editing. The Prime Editing technology is a next-generation technology that can search and replace to restore normal genetic function in the genome and can treat a wide spectrum of diseases with high unmet medical needs. Additional info from NASDAQ: |
Prime Medicine Announces New Zealand Clearance of Clinical Trial Application for PM577a in H1069Q-mutated Wilson Disease
Read moreDirector Schenkein David P 🟢 acquired 75.0K shares (1 derivative) of Prime Medicine, Inc. (PRME) at $3.06 Transaction Date: Jun 05, 2026 | Filing ID: 041579
Read moreDirector NELSEN ROBERT 🟢 acquired 75.0K shares (1 derivative) of Prime Medicine, Inc. (PRME) at $3.06 Transaction Date: Jun 05, 2026 | Filing ID: 041572
Read moreDirector Kelly Michael Aaron 🟢 acquired 75.0K shares (1 derivative) of Prime Medicine, Inc. (PRME) at $3.06 Transaction Date: Jun 05, 2026 | Filing ID: 041569
Read moreDirector Foster-Cheek Kaye I 🟢 acquired 75.0K shares (1 derivative) of Prime Medicine, Inc. (PRME) at $3.06 Transaction Date: Jun 05, 2026 | Filing ID: 041566
Read moreDirector Chung Wendy 🟢 acquired 75.0K shares (1 derivative) of Prime Medicine, Inc. (PRME) at $3.06 Transaction Date: Jun 05, 2026 | Filing ID: 041560
Read moreDirector Cahill Thomas 🟢 acquired 75.0K shares (1 derivative) of Prime Medicine, Inc. (PRME) at $3.06 Transaction Date: Jun 05, 2026 | Filing ID: 041553
Read more(30% Negative) PRIME MEDICINE, INC. (PRME) Reports Q2 2026 Financial Results
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT07226622 | Prescreening Study to Identify Potential Wilson Disease Participants for Gene-E… | — | Wilson Disease | Active_Not_Recruiting | 2025-12-29 | 2027-12-01 | ClinicalTrials.gov |
| NCT06559176 | A Study of the Safety and Efficacy of Prime Editing (PM359) in Participants Wit… | Phase1 | Chronic Granulomatous Disease | Enrolling_By_Invitation | 2024-10-17 | 2030-02-01 | ClinicalTrials.gov |
| NCT06333730 | Comparison of Anesthetic Efficacy of Mental Nerve Block Versus Inferior Alveola… | Na | Symptomatic Irreversible Pulpitis | Unknown | 2024-04-01 | 2024-06-20 | ClinicalTrials.gov |
| NCT05895526 | Comparison of the Effectiveness of Self Etch Adhesive and Fluoride Varnish in R… | Na | Dentin Sensitivity | Unknown | 2023-06-12 | 2023-08-12 | ClinicalTrials.gov |
| NCT05574088 | Comparison of Postoperative Pain With or Without Apical Patency Technique in As… | Na | Pain, Postoperative | Completed | 2022-09-01 | 2022-11-30 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Apical patency with file | Other | Approved | Pain, Postoperative | COMPLETED | NCT05574088 |
| Self etch dentin adhesive, Fluoride varnish | Other | Approved | Dentin Sensitivity | UNKNOWN | NCT05895526 |
| mental nerve block | Other | Approved | Symptomatic Irreversible Pulpitis | UNKNOWN | NCT06333730 |
| inferior alveolar nerve block | Other | Approved | Symptomatic Irreversible Pulpitis | UNKNOWN | NCT06333730 |
| PM359 | Other | Phase PHASE1 | Chronic Granulomatous Disease | ENROLLING_BY_INVITATION | NCT06559176 |
| PM359 | BIOLOGICAL | Phase PHASE1 | Chronic Granulomatous Disease | ENROLLING_BY_INVITATION | NCT06559176 |